Relay Therapeutics Quarterly Income Statement
NASDAQ: RLAYHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Relay Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Relay Therapeutics generated $350,000 in revenue, down 48.3% from the same quarter a year earlier. Relay Therapeutics reported a net loss of $83.7 million, compared with a loss of $70.4 million a year earlier. Operating margin was -25949.7%.
Diluted earnings per share came in at -$0.41.
Summary generated from market data by MetaCap's automated system. Methodology
Relay Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 350.00K | 3.00M | 7.00M | 0 | 677.00K | 7.68M | 0 | 0 | 0 | 10.01M | -1.00K | 25.20M |
| Revenue growth (YoY) | -48.30% | -60.93% | — | — | — | -23.26% | — | -100.00% | -100.00% | +4327.88% | -100.40% | +7226.16% |
| Operating Expenses | 91.17M | 81.59M | 67.63M | 80.39M | 77.52M | 92.55M | 84.98M | 96.37M | 100.76M | 100.37M | 92.19M | 98.78M |
| Research & Development | 76.48M | 70.56M | 55.41M | 68.26M | 63.90M | 73.81M | 68.08M | 76.62M | 91.99M | 82.40M | 77.50M | 81.49M |
| Operating Income | -90.82M | -78.59M | -60.63M | -80.39M | -76.85M | -84.87M | -84.98M | -96.37M | -100.76M | -90.36M | -92.20M | -73.58M |
| Other Income (Expense) | 7.12M | 5.30M | 5.74M | 6.24M | 6.47M | 7.80M | 8.97M | 8.26M | 8.54M | 8.98M | 8.70M | 7.84M |
| Net Income | -83.71M | -73.29M | -54.89M | -74.15M | -70.38M | -77.06M | -76.00M | -88.11M | -92.21M | -81.39M | -83.50M | -65.73M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.41 | -0.41 | -0.31 | -0.43 | -0.41 | -0.46 | -0.42 | -0.63 | -0.69 | -0.62 | -0.66 | -0.54 |
| EPS (Diluted) | -0.41 | -0.41 | -0.31 | -0.43 | -0.41 | -0.46 | -0.42 | -0.63 | -0.69 | -0.62 | -0.66 | -0.54 |
| Shares Outstanding (Basic) | 202.85M | 179.85M | — | 172.39M | 171.26M | 169.23M | — | 140.23M | 132.82M | 130.84M | — | 122.23M |
| EBITDA | -90.46M | -78.09M | -60.03M | -79.64M | -75.84M | -83.66M | -83.64M | -95.00M | -99.39M | -88.97M | -90.82M | -72.21M |
| Operating Margin | -25949.71% | -2619.67% | -866.14% | — | -11351.11% | -1105.21% | — | — | — | -903.00% | 9219600.00% | -291.95% |
| Net Margin | -23916.29% | -2443.03% | -784.14% | — | -10395.13% | -1003.58% | — | — | — | -813.30% | 8349500.00% | -260.83% |
This table shows 12 quarterly periods of Relay Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 13 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow RLAY's reporting calendar. What is a income statement?